Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

300
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
300

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying Minimum Threshold Level of Trial Crossover Rates Yielding Nonsignificant Overall Survival Benefit Associated with Cancer Treatments: A Systematic Literature Review of HTA Submissions.

Journal of health economics and outcomes research·2026
Same author

Choosing Covariate Balancing Methods for Causal Inference: Practical Insights From a Simulation Study.

Statistics in medicine·2026
Same author

The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone.

British journal of cancer·2026
Same author

Innovative Clinical Trial Approach for Evaluating Digital Medical Devices Under European Fast-Track Regulatory Frameworks.

Statistics in medicine·2026
Same author

Automated Cardiac Arrest Detection Using Wrist-Worn Photoplethysmography: External Validation in Patients With Induced Shockable Cardiac Arrest (DETECT-1b).

Circulation. Arrhythmia and electrophysiology·2026
Same author

A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence.

Pharmacoepidemiology and drug safety·2026

Related Experiment Video

Updated: May 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.3K

Decision-Making Criteria and Methods for Initiating Late-Stage Clinical Trials in Drug Development From a

Ce Jiang1, Céline Beji2, Sonia Zebachi1

  • 1Quinten Health, Paris, France.

Clinical Pharmacology and Therapeutics
|February 20, 2025
PubMed
Summary

Drug development decisions require considering multiple stakeholder needs beyond just efficacy. This review explores broader probability of success metrics for better phase II to III transition decision-making.

More Related Videos

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

11.7K
Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
06:16

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Published on: June 6, 2020

3.5K

Related Experiment Videos

Last Updated: May 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.3K
A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

11.7K
Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
06:16

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Published on: June 6, 2020

3.5K

Area of Science:

  • Drug development decision-making
  • Quantitative methodologies in clinical trials
  • Stakeholder analysis in pharmaceutical R&D

Background:

  • Drug development relies on critical go/no-go decisions, especially transitioning from early to late-stage trials.
  • Current quantitative methods for decision-making often overlook diverse stakeholder priorities.
  • A comprehensive approach is needed to integrate various perspectives for robust decision-making.

Purpose of the Study:

  • To examine decision-making criteria and methods at the phase II to III transition.
  • To broaden the concept of probability of success (PoS) beyond efficacy to include regulatory, market, and financial aspects.
  • To identify limitations in current methodologies and propose paths for improvement.

Main Methods:

  • Scoping review of decision-making criteria and methods for phase II to III transition.
  • Analysis of probability of success (PoS) for various success definitions (regulatory, market access, financial, competitive).
  • Identification of key themes including decision criteria, trial design, utility-based approaches, financial metrics, and multi-stakeholder considerations.

Main Results:

  • Current methodologies for decision-making in drug development have limitations in fully accounting for diverse stakeholder needs.
  • The probability of success (PoS) concept can be expanded beyond efficacy to encompass regulatory approval, market access, financial viability, and competitive performance.
  • Key themes identified include decision criteria selection, trial design optimization, utility-based approaches, financial metrics, and multi-stakeholder considerations.

Conclusions:

  • There is a need to move beyond efficacy-focused probability of success (PoS) in late-stage drug development decisions.
  • Integrating real-world data (RWD) and advanced analytics can enhance decision-making processes.
  • Future approaches should aim for a more balanced, data-driven, and stakeholder-aligned decision-making framework for clinical trial transitions.